News Release

United States of America Patent Issued for Tetrodin(HT)

Date: 1998/07/29

We have today received notification of our first patent issuance since filing and receiving approval of the European Patent Application in February 1997. The significance of this USA Patent is that the United States in 1989, along with the vast majority of the developed countries in the world, signed the International Reciprocity Treaty on Patents and Intellectual Properties. This treaty documents that the signing participants will respect the ownership and right afforded the owner of any USA or participating countries, current and/or new patent. Any country under this treaty that does not protect and defend a patent holder would be subject to a number of penalties, some of which could be the loss of membership and/or access to the International Monetary Fund and the World Bank.

Notwithstanding that issue, we believe this USA patent issuance will further cause to bring Tetrodin (HT) to the attention of the market, the government, and the medical community of the USA.

Tetrodin (HT) is a non-addictive, non-narcotic, strong and long lasting analgesic, that has been demonstrated to be a safe and cost effective cure for opiate(s) (opium, heroin, morphine, methadone, etc.) drug addictions. It has demonstrated in testing unparalleled success when used as either a "primary drug withdrawal" treatment product or as a longer-term drug addiction treatment product, having no serious side effects nor will it cause any further addiction.

For additional information on Tetrodin (HT), view the IWT website at http://www.wextech.ca or call Howard Milne at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary